Browse > Article

Sputum Smear Conversion During mDOT (Modified Directly Observed Treatment)  

Hwang, Taik Gun (Health Center, Kangnam District)
Kim, Soon Deok (Department of Preventive Medicine, College of Medicine, Korea University)
Yoo, Se Hwa (Respiratory Division, Department of Internal Medicine, Korea University Medical Center)
Shin, Yoo Chul (Department of Family Medicine, Seoul Paik Hospital, Inje University)
Publication Information
Tuberculosis and Respiratory Diseases / v.56, no.5, 2004 , pp. 485-494 More about this Journal
Abstract
Background : To assess the effects of mDOT implementation on sputum smear conversion for AFB (Acid fast bacilli) positive pulmonary tuberculosis patients, modified Directly Observed Treatment (mDOT) was started on October $8^{th}$ 2001 at a health center in Seoul. mDOT was defined through weekly interviewing and supervising of a patient by a supervisor (doctor, nurse, or lay health worker). The sputum smear conversion of a mDOT group was compared with that of a self-medication (self) group. Methods : This study included 52 AFB positive pulmonary tuberculosis patients registered at a health center in Seoul between October $8^{th}$ 2001 and April $23^{rd}$ 2002. 24 and 28 patients were enrolled in the mDOT and self medication groups, respectively. Paired (1:1) individual matching, by gender, extent of disease, relapse and age-matching variables, was performed between the two groups, resulting in 20 paired matches. This prospective study was planned as an unblinded, non-randomized quasiexperimental pilot project. Outcomes were identified from results of sputum smear examinations for AFB in both groups at 2 weeks, and 1 and 2 months. The paired matching data were analyzed using the SAS program version 8.1 by McNemar test. Results : At the end of 2 weeks of treatment, the sputum smear conversion of the mDOT group was somewhat higher than that of the self medication group (78.57 vs. 50%, p-value=0.289), and after 1 month of treatment no statistically significant difference was shown between the two groups (83.33 vs. 50, p-value=0.125). At the end of 2 months of treatment (initial intensive phase), the sputum smear conversions of the mDOT and self groups were 95 and 75%, respectively (p-value=0.219). Conclusions : The implementation of mDOT did not result in clinically significant increases in the sputum smear conversion at 2 weeks, and 1 and 2 months compared with that of the self medication group. However, the increases experienced might contribute to diminishing the infectious period of AFB positive patients, and this approach may act as a guide for a specific group of patients. In this study, mDOT was performed for one hundred percent of the intensive treatment phase. It can also be an effective treatment for pulmonary tuberculosis patients, and may be useful for some high risk tuberculosis patients.
Keywords
AFB positive pulmonary tuberculosis; mDOT; Sputum smear conversion;
Citations & Related Records

Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Dick J, Schoeman JH, Mohammed A, Lom-bard C. Tuberculosis in the community: 1.Evaluation of a volunteer health worker pro-gramme to enhance adherence to anti-tuber-culosis treatment. Tubercle Lung Dis 1996;77:247-9
2 Crofton J, Chaulet P, Maher D. Guidelines for the management of drug-resistance tube-rculosis. WHO/TB/96.210. Geneva: WHO, 1997
3 Enarson DA, Rieder HL, Arnadottir T. Tuber-culosis guide for low income countries. 3rd ed. Paris: International Union Against Tuber-culosis and Lung Disease, 1994
4 World Health Organization. What is DOTS? A Guide to Understanding the WHO-recom-mended TB Control Strategy Known as DOTS. WHO/CDS/ CPC/TB/99.270. 1999
5 World Health Organization. Tuberculosis Programme. Framework for effective tuber-culosis control. WHO/TB/94.179. 1994
6 국립보건원 방역과, 결핵연구원. 2001년도 국가결핵관리사업 평가. 2001
7 Maher D, Chaulet P, Spinaci S, Harries A. Treatment of tuberculosis: guidelines for na-tional programmes. 2nd ed. 1997. World Heal-th Organization, Geneva, Switzerland, WHO/TB/97.220
8 Farmer P. Managerial successes, clinical failures. Int J Tuberc Lung Dis 1999;3:365-7
9 Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization(Leading article). Tubercle 1991;72:1-6
10 Akkslip S, Rasmithat S, Maher D, Sawert H. Direct observation of tuberculosis treatment by supervised family members in Yasothorn Province, Thailand. Int J Tuberc Lung Dis 1999;3(12):1061-5
11 Zalesky R, Abdullajev F, Khechinashvili G, et al. Tuberculosis control in the Caucasus:successes and constraints in DOTS imple-mentation. Int J Tuberc Lung Dis 1999;3(5):394-401
12 World Health Organization. An Expanded DOTS Framework for effective Tuberculosis Control. WHO/CDS/TB/2002.297. 2002
13 Lambregts-van Weezenbek KSB, Reichman LB. DOTS and DOTS-Plus : what's in a name. Int J Tuberc Lung Dis 2000;4(11):995-6
14 Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse of tuber-culosis. N Engl J Med 1994;330:1179-84
15 Farmer P, Kim JY, Mitnick C, Timperi R. Responding to outbreaks of multidrug-resi-stant tuberculosis--introducing DOTS PLUS. In: Reichman LB, Hershfield E. Tuberculosis: a comprehensive international approach. 2nd ed. New York: Marcel Dekker Inc., 2000. In Press
16 서울특별시. 2001년 결핵사업관리평가서. 2002
17 SAS, SAS proprietary software release 8.1.Cary, NC: SAS institute, Inc., USA
18 Rieder HL. Sputum smear conversion during directly observed treatment for tuberculosis. Tubercle Lung Dis 1996;77:124-9
19 Balasubramanian VN, Oommen K, Samuel R. DOT or not? Direct observation of anti-tu-berculosis treatment and patient outcomes, Kerala State, India. Int J Tuberc Lung Dis 2000;4(5):409-13
20 Gordis L. Epidemiology. 2nd ed. WB Saun-ders Co.; 2000. p. 148-149
21 홍영표. 우리나라 결핵관리. 건강보장연구 1999;3:111-48
22 World Health Organization. Tuberculosis: a global emergency(WHO Notes & News). World Health Forum 1993;14:438
23 Hurtig AK, Porter JDH, Ogden JA. Tuber-culosis control and directly observed therapy from the public health/human rights perspec-tive. Int J Tuberc Lung Dis 1999;3:553-60